Clinical Biostatistics & Data Analysis

Randomization Considerations in DCT and Hybrid Clinical Trial Models

Posted on By digi

Randomization Considerations in DCT and Hybrid Clinical Trial Models Randomization Considerations in DCT and Hybrid Clinical Trial Models In recent years, the landscape of clinical trials has significantly shifted toward decentralized clinical trials (DCTs) and hybrid models, which integrate elements of traditional and remote methodologies. Central to the success of any clinical trial—be it traditional,…

Read More “Randomization Considerations in DCT and Hybrid Clinical Trial Models” »

Randomization Lists & IAM

Audit Trails and Access Controls for Randomization and IAM Systems

Posted on By digi

Audit Trails and Access Controls for Randomization and IAM Systems Audit Trails and Access Controls for Randomization and IAM Systems The advent of technology in clinical trials has significantly transformed how data is managed, especially in randomized trials. Randomization is a critical component for ensuring the validity of a clinical study, and the integrity of…

Read More “Audit Trails and Access Controls for Randomization and IAM Systems” »

Randomization Lists & IAM

Case Studies: Randomization Breakdowns and How They Were Resolved

Posted on By digi

Case Studies: Randomization Breakdowns and How They Were Resolved Case Studies: Randomization Breakdowns and How They Were Resolved Randomization is a crucial component of clinical trials, ensuring that treatment allocation is unbiased and that the results are valid. However, issues can arise during the randomization process, posing challenges to the integrity of a study. In…

Read More “Case Studies: Randomization Breakdowns and How They Were Resolved” »

Randomization Lists & IAM

Working Effectively With Vendors on Randomization Design and Execution

Posted on By digi

Working Effectively With Vendors on Randomization Design and Execution Working Effectively With Vendors on Randomization Design and Execution In the realm of clinical research, particularly within the scope of clinical trials, the design and execution of randomization play critical roles in ensuring the integrity and validity of study results. This step-by-step tutorial aims to guide…

Read More “Working Effectively With Vendors on Randomization Design and Execution” »

Randomization Lists & IAM

Statistical Analysis Plans (SAP): Blueprint for Credible Trial Results

Posted on By digi

Statistical Analysis Plans (SAP): Blueprint for Credible Trial Results Statistical Analysis Plans (SAP): Blueprint for Credible Trial Results In the complex landscape of clinical trials, the importance of a robust Statistical Analysis Plan (SAP) cannot be overstated. It serves as a blueprint outlining how data will be analyzed, interpreted, and reported, providing transparency and rigor…

Read More “Statistical Analysis Plans (SAP): Blueprint for Credible Trial Results” »

Statistical Analysis Plans (SAP)

Structuring the SAP to Align With Protocol, Estimands and Regulatory Goals

Posted on By digi

Structuring the SAP to Align With Protocol, Estimands and Regulatory Goals Structuring the SAP to Align With Protocol, Estimands and Regulatory Goals In the realm of clinical trials, particularly in studies involving non-small cell lung cancer (NSCLC), the Statistical Analysis Plan (SAP) plays a pivotal role in guiding the analysis of trial data. This article…

Read More “Structuring the SAP to Align With Protocol, Estimands and Regulatory Goals” »

Statistical Analysis Plans (SAP)

Defining Analysis Populations: ITT, mITT, PP and Safety Sets

Posted on By digi

Defining Analysis Populations: ITT, mITT, PP and Safety Sets Defining Analysis Populations: ITT, mITT, PP and Safety Sets In clinical research, the selection and definition of analysis populations is a critical aspect of statistical analysis plans (SAPs). Properly categorizing participants into appropriate analysis populations is essential for ensuring accurate and regulatory-compliant results. This step-by-step guide…

Read More “Defining Analysis Populations: ITT, mITT, PP and Safety Sets” »

Statistical Analysis Plans (SAP)

Pre-Specifying Primary, Secondary and Exploratory Analyses in the SAP

Posted on By digi

Pre-Specifying Primary, Secondary and Exploratory Analyses in the SAP Pre-Specifying Primary, Secondary and Exploratory Analyses in the Statistical Analysis Plan (SAP) The Statistical Analysis Plan (SAP) is a critical component of clinical trials, guiding how data will be analyzed and interpreted. Pre-specifying primary, secondary, and exploratory analyses ensures that the analysis yields relevant, scientifically valid…

Read More “Pre-Specifying Primary, Secondary and Exploratory Analyses in the SAP” »

Statistical Analysis Plans (SAP)

Handling Multiplicity, Interim Analyses and Sensitivity Analyses in SAPs

Posted on By digi

Handling Multiplicity, Interim Analyses and Sensitivity Analyses in SAPs Handling Multiplicity, Interim Analyses and Sensitivity Analyses in SAPs Understanding Multiplicity in Clinical Trials Multiplicity in clinical trials refers to the occurrence of multiple comparisons or analyses that could potentially distort results and lead to false conclusions. This increases the likelihood of Type I errors, where…

Read More “Handling Multiplicity, Interim Analyses and Sensitivity Analyses in SAPs” »

Statistical Analysis Plans (SAP)

SAP Development Workflows Between Clinicians, Biostatisticians and Regulators

Posted on By digi

SAP Development Workflows Between Clinicians, Biostatisticians and Regulators SAP Development Workflows Between Clinicians, Biostatisticians and Regulators In the realm of clinical research, establishing clear workflows for the development of Statistical Analysis Plans (SAP) is paramount. Effective collaboration between clinicians, biostatisticians, and regulators not only meets regulatory requirements but also enhances the quality of data collected…

Read More “SAP Development Workflows Between Clinicians, Biostatisticians and Regulators” »

Statistical Analysis Plans (SAP)